GRAIL, LLC saw a significant uptick in its stock price following positive developments related to its cancer detection technology.
GRAIL, LLC (NASDAQ:GRAL) experienced a notable surge in its stock price, climbing 7.55% in yesterday's session. This increase comes on the heels of encouraging news regarding its multi-cancer early detection test, Galleri.
Advertisement
GRAIL, LLC
GRAL.US
GRAL.US
GRAIL, LLC
WealthAwesomeMarket cap
$6.88B
52W high
$156.49
52W low
$41.50
1W change
+16.17%
Beta
2.84
Analyst Price Targets
Based on analyst covering GRAL · as of Oct 5, 2026
Wall Street analysts forecast GRAL stock price to fall 27.1% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$112.40
-27.1% Upside
Previously C$97.40 on Sep 29, 2026
Current Price
C$154.08
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GRAL's historical volatility
30-Day Vol
103.9%
Annualized
90-Day Vol
88.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$184.20
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$163.53 | C$114.27 – C$234.03 |
| 60 trading days | C$173.56 | C$104.54 – C$288.15 |
| 90 trading days | C$184.20 | C$99.00 – C$342.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent FDA advisory committee vote supporting Galleri's safety and effectiveness has bolstered investor confidence, highlighting the potential for GRAIL to capture a significant market share in cancer diagnostics.
7.55%
GRAIL's stock price increased by 7.55% following positive FDA panel feedback, reflecting strong investor interest in the company's future prospects.
Bull case
With the FDA advisory committee's favorable vote, GRAIL is in a good position to secure regulatory approval for Galleri. This could lead to widespread adoption and increased revenue as the test gains traction in the healthcare market.
Bear case
Despite the positive momentum, GRAIL faces challenges with the actual adoption of Galleri by healthcare providers and insurers. There are ongoing concerns about its profitability and high cash burn rate.
Advertisement
Positive FDA Panel Vote
The recent FDA advisory committee vote supporting the safety and effectiveness of GRAIL's Galleri test has been a pivotal moment for the company. This backing enhances Galleri's credibility and paves the way for potential regulatory approval, which could significantly impact GRAIL's market position.
Market Implications and Future Prospects
The surge in GRAIL's stock reflects investor optimism about personalized cancer screening's future. However, the company must navigate challenges related to insurance coverage and market adoption to capitalize on this momentum. Analysts remain divided on whether GRAIL can sustain its growth trajectory amidst these hurdles.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
